Novo obesity drug seen with 43 percent chance of approval
COPENHAGEN (Reuters) - Danish group Novo Nordisk's diabetes drug Victoza has a 43 percent chance of being approved as an obesity treatment in the United States, according to a Reuters poll which found Danish bank analysts had the highest expectations. (Source: Reuters: Health)
National evaluation of the Department of Health's integrated care pilots
This report is the final output of an evaluation of the 16 Department of Health Integrated Care Pilots. The report covers the main findings, efforts and inputs, and facilitators and barriers to success of each pilot, and provides an account of the evaluation activities conducted, the data collected and the analyses completed.
Report
Department of Health - publications (Source: The Kings Fund - Health Management Specialist Collection)div id=medwormpbiMedWorm Sponsor Message:/i/b Have a look at a href=http://www.thepsychologydaily.comThe Psychology Daily/a, the new psychology portal powered by MedWorm, with all the latest psychology news and research updated daily./p/div
